These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 10686314)

  • 21. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience.
    El-Sabrout R; Delaney V; Qadir M; Butt F; Hanson P; Butt KM
    Transplant Proc; 2003 May; 35(3 Suppl):89S-94S. PubMed ID: 12742474
    [No Abstract]   [Full Text] [Related]  

  • 22. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
    Forsythe J
    Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
    [No Abstract]   [Full Text] [Related]  

  • 23. A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus.
    Daoud AJ; Schroeder TJ; Shah M; Hariharan S; Peddi VR; Weiskittel P; First MR
    Transplant Proc; 1998 Dec; 30(8):4079-81. PubMed ID: 9865303
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical study of FK 506 in renal transplant recipients.
    Youhua Z; Zhinlian M; Liming W
    Transplant Proc; 2000 Nov; 32(7):1704. PubMed ID: 11119900
    [No Abstract]   [Full Text] [Related]  

  • 26. Randomized trial of immunosuppressive regimens in renal transplantation.
    Guerra G; Ciancio G; Gaynor JJ; Zarak A; Brown R; Hanson L; Sageshima J; Roth D; Chen L; Kupin W; Tueros L; Ruiz P; Livingstone AS; Burke GW
    J Am Soc Nephrol; 2011 Sep; 22(9):1758-68. PubMed ID: 21807891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 30. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
    Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
    Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
    [No Abstract]   [Full Text] [Related]  

  • 31. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
    Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
    Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
    Krämer BK; Krüger B; Mack M; Obed A; Banas B; Paczek L; Schlitt HJ
    Transplant Proc; 2005 May; 37(4):1789-91. PubMed ID: 15919467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress with cyclosporine-sparing regimens.
    Grinyó JM
    Transplant Proc; 1999 Dec; 31(8A):11S-16S. PubMed ID: 10616555
    [No Abstract]   [Full Text] [Related]  

  • 34. Sirolimus antirejection therapy for renal transplantation with cyclosporine-based immunosuppression: case reports.
    Tsai MK; Hu RH; Lee PH
    Transplant Proc; 2003 Feb; 35(1):219-20. PubMed ID: 12591371
    [No Abstract]   [Full Text] [Related]  

  • 35. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation.
    Weir MR
    Transplant Proc; 2001 Jun; 33(4 Suppl):19S-28S. PubMed ID: 11406264
    [No Abstract]   [Full Text] [Related]  

  • 37. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation.
    Bruce DS; Woodle ES; Newell KA; Millis JM; Cronin DC; Loss GE; Grewal HP; Siegel CT; Pellar S; Josephson MA; Thistlethwaite JR
    Transplant Proc; 1998 Jun; 30(4):1538-40. PubMed ID: 9636625
    [No Abstract]   [Full Text] [Related]  

  • 38. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Improved immunosuppression leads to better kidney transplantations].
    Ekberg H
    Lakartidningen; 2012 Sep 26-Oct 9; 109(39-40):1739-42. PubMed ID: 23097879
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
    Jurewicz WA
    Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.